Close Menu

NEW YORK (GenomeWeb) – Metastatic breast cancer tumors that express the estrogen receptor often acquire HER2 mutations that make them resistant to treatments targeting the estrogen receptor.

About 80 percent of breast cancers are ER+, according to the National Institutes of Health. According to a team led by researchers at the Dana-Farber Cancer Institute, nearly all patients with ER+breast cancers that become metastatic develop resistance to treatments that target the estrogen receptor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.